OverviewSuggest Edit

BenevolentAI is a company engaged in the development and application of artificial intelligence for drug discovery and development. Its platform empowers scientists to decipher the complex code underlying human biology and find new ways to treat disease.

HQLondon, GB
Employee Ratings3.8

Latest Updates

Employees (est.) (Sept 2020)272(+6%)
Job Openings10
Revenue (FY, 2018)£6.8 M(+165%)
Cybersecurity ratingAMore

Key People/Management at BenevolentAI

Ken Mulvany

Ken Mulvany

Founder and Chairman
Joanna Shields

Joanna Shields

Ivan Griffin

Ivan Griffin

COO & Co-Founder
Alix Lacoste

Alix Lacoste

VP Data Science
Anne Phelan

Anne Phelan

Ben Medlock

Ben Medlock

Show more

BenevolentAI Office Locations

BenevolentAI has offices in London, Babraham and Brooklyn
London, GB (HQ)
4-8 Maple St, Bloomsbury
Babraham, GB
Babraham Hall House
Brooklyn, US
1 Dock 72 Way, 7th Floor
Show all (3)

BenevolentAI Financials and Metrics

Summary Metrics

Founding Date


BenevolentAI total Funding

$305 m

BenevolentAI latest funding size

$90 m

Time since last funding

a year ago

BenevolentAI investors

BenevolentAI's latest funding round in September 2019 was reported to be $90 m. In total, BenevolentAI has raised $305 m. BenevolentAI's latest valuation is reported to be $1 b.
View all funding rounds

BenevolentAI Revenue

Embed Graph
View revenue for all periods
BenevolentAI's revenue was reported to be £6.83 m in FY, 2018 which is a 164.1% increase from the previous period.

Revenue (FY, 2018)


Revenue growth (FY, 2017 - FY, 2018), %


Gross profit (FY, 2018)


Gross profit margin (FY, 2018), %


Net income (FY, 2018)


EBIT (FY, 2018)


Market valuation


Cash (31-Dec-2018)

GBPFY, 2017FY, 2018



Revenue growth, %


Gross profit


Gross profit Margin, %

GBPFY, 2017FY, 2018



Prepaid Expenses


Current Assets



GBPFY, 2017FY, 2018

Net Income


Depreciation and Amortization


Accounts Payable


Cash From Operating Activities

GBPFY, 2017



Financial Leverage

0.6 x
Show all financial metrics

BenevolentAI Operating Metrics

May, 2020

Trademarks Pending

Show all operating metrics

BenevolentAI Acquisitions / Subsidiaries

Company NameDateDeal Size
BenevolentAI Cambridge LimitedFebruary 21, 2018
BenBio GK
BenevolentAI Bio Limited
BenevolentAI Energy Limited
BenevolentAI Technology Inc
BenevolentAI Technology Limited

BenevolentAI Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

BenevolentAI Revenue Breakdown

Embed Graph

BenevolentAI revenue breakdown by business segment: 91.4% from License Revenue and 8.6% from Rendering of Services

BenevolentAI revenue breakdown by geographic segment: 90.3% from Europe, 8.6% from USA and 1.2% from Other

Human Capital Metrics

Embed Graph
Show all human capital metrics

BenevolentAI Online and Social Media Presence

Embed Graph

BenevolentAI News and Updates

How BenevolentAI bounced back from a $1 billion loss

When London tech startup BenevolentAI secured a $90 million (£68 million) cash injection from Singaporean sovereign fund Temasek in September 2019, the deal valued the business at $1 billion. Not bad for a six-year-old company whose ambition to dramatically change the way drugs are discovered and de…

COVID-19 update: Possible cure found by BenevolentAI

By using high-end BenevolentAI technologies, a possible treatment was found and pinpointed in such a speedy manner that shocked the company that makes the said drug, and as well as the other doctors who had spent years into researching about the effects on other viruses.

In the time of Covid pandemic, AI comes to the rescue

An Artificial Intelligence (AI) software developed by BenevolentAI, a London-based startup has created a super search engine that combines the data from the drug industry data and chunks of new information garnered from scientific research papers.

AI could cure coronavirus: London-based BenevolentAI enters clinical trials

In this regard, BenevolentAI, a London-based company that creates and applies AI and machine learning to transform the way medicines are discovered and developed has announced that baricitinib, which it identified this year as a potential treatment for COVID-19, will be entering late-stage phase 3 c…

BenevolentAI analyses approved drug as potential Covid-19 treatment

BenevolentAI has used artificial intelligence to identify and analyse an approved drug that may have potential as a coronavirus treatment.

Startup Profile: Benevolent AI

BenevolentAI is a drug development startup founded by Kev Mulvany in 2013. The company has since raised $292 million in funding. BenevolentAI is using Its artificial intelligence platform to search for a Coronavirus cure.
Show more

BenevolentAI Blogs

Teaming up to fuel scientific discovery in CCM research

We partnered with UC San Diego to investigate new approaches to develop non-invasive therapeutic treatments for Cerebral Cavernous Malformations. In this blog, Benevolent’s Senior Principal Scientist shares insights into his work to use AI to identify new targets associated with this rare diseas…

MIT Technology Review names BenevolentAI as a top 10 breakthrough tech

We’re proud to be recognised on this prestigious list for our work in AI-driven chemical design. Our compound design is based upon complex multiparametric optimisations which aim to cut the time and cost of designing a drug by years.

BenevolentAI announces scientific collaboration with UC San Diego to investigate Cerebral Cavernous Malformations

BenevolentAI announces scientific collaboration with UC San Diego to investigate Cerebral Cavernous Malformations. The joint partnership will focus on developing a therapy for CCM - a highly rare disease that currently has no effective treatment

Working together to meet a ‘moonshot moment’ in drug discovery and development

Joanna Shields addresses AstraZeneca’s scientists and explains how true collaboration between human expertise and technology will help us rise to our moonshot moment.

One team, one mission: nurturing a culture of innovation and collaboration

Like all fast-growth companies, we face the challenge of balancing the need to build and scale quality products while also finding time to explore radical new idea. We rose to the challenge the Benevolent way by creating Break-Out Week, a whole week dedicated to creativity and testing new ideas.

Introducing our latest research at NeurIPS2019

Machine learning and artificial intelligence represent an incredible opportunity for the health sector. Our team of AI and biomedical scientists present their latest research at NeurIPS 2019
Show more

BenevolentAI Frequently Asked Questions

  • When was BenevolentAI founded?

    BenevolentAI was founded in 2013.

  • Who are BenevolentAI key executives?

    BenevolentAI's key executives are Ken Mulvany, Joanna Shields and Ivan Griffin.

  • How many employees does BenevolentAI have?

    BenevolentAI has 272 employees.

  • What is BenevolentAI revenue?

    Latest BenevolentAI annual revenue is £6.8 m.

  • What is BenevolentAI revenue per employee?

    Latest BenevolentAI revenue per employee is £25.1 k.

  • Who are BenevolentAI competitors?

    Competitors of BenevolentAI include LabGenius, SOM Biotech and Paige.

  • Where is BenevolentAI headquarters?

    BenevolentAI headquarters is located at 4-8 Maple St, Bloomsbury, London.

  • Where are BenevolentAI offices?

    BenevolentAI has offices in London, Babraham and Brooklyn.

  • How many offices does BenevolentAI have?

    BenevolentAI has 3 offices.